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Objective. Inclusion body myositis (IBM) is char-
acterized by a combination of inflammatory and degener-
ative changes affecting muscle. While the primary cause
of IBM is unknown, genetic factors may influence disease
susceptibility. To determine genetic factors contributing
to the etiology of IBM, we conducted the largest genetic
association study of the disease to date, investigating
immune-related genes using the Immunochip.
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Methods. A total of 252 Caucasian patients with
IBM were recruited from 11 countries through the Myo-
sitis Genetics Consortium and compared with 1,008 eth-
nically matched controls. Classic HLA alleles and
amino acids were imputed using SNP2HLA.
Results. The HLA region was confirmed as the most
strongly associated region in IBM (P5 3.583 10233). HLA
imputation identified 3 independent associations (with
HLA–DRB1*03:01, DRB1*01:01, and DRB1*13:01), al-
though the strongest association was with amino acid posi-
tions 26 and 11 of the HLA–DRB1 molecule. No association
with anti–cytosolic 50-nucleotidase 1A–positive status was
found independent ofHLA–DRB1*03:01. There was no asso-
ciation of HLA genotypes with age at onset of IBM. Three
non-HLA regions reached suggestive significance, including
the chromosome 3 p21.31 region, an established risk locus
for autoimmune disease, where a frameshift mutation in
CCR5 is thought to be the causal variant.
Conclusion. This is the largest, most comprehen-
sive genetic association study to date in IBM. The data
confirm that HLA is the most strongly associated region
and identifies novel amino acid associations that may
explain the risk in this locus. These amino acid associations
differentiate IBM from polymyositis and dermatomyositis
and may determine properties of the peptide-binding
groove, allowing it to preferentially bind autoantigenic
peptides. A novel suggestive association within the chromo-
some 3 p21.31 region suggests a role forCCR5.
Sporadic inclusion body myositis (IBM) is an
acquired muscle disease characterized clinically by weakness
and muscle wasting, predominantly of the quadriceps and
long finger flexor muscles. While degenerative changes are
recognized, there are also immune-mediated mechanisms at
play, characterized by inflammatory features inmuscle biopsy
specimens and the presence of circulating autoantibodies.
These autoantibodies include anti-Ro and a recently identi-
fied autoantibody directed against cytosolic 50-nucleotidase
1A (anti-cN1A), which is present in approximately one-third
of patients (1,2). While the primary cause of the disease
remains unknown, genetic factors may influence disease sus-
ceptibility. A group of hereditary diseases that includes the
hereditary inclusion body myopathies and other muscular
dystrophies such as the myofibrillary myopathies may mimic
clinical features of IBM (3). These diseases may also exhibit
similar pathologic features, such as rimmed vacuoles and pro-
tein accumulations; clinical and histopathologic suspicion of
these diseases should prompt appropriate genetic testing.
To date, the strongest genetic risk identified for IBM
lies within the major histocompatibility complex (MHC), in
particular with HLA–DRB1*03:01, an allele present on the
8.1 ancestral haplotype that is a risk factor for many
autoimmune diseases, including the idiopathic inflammatory
myopathies (IIMs) (4). Other HLA–DRB1 alleles such as
HLA–DRB1*01:01 and HLA–DRB1*13:01 have also been
implicated in IBM, and genotypic combinations of these
alleles have been reported to correlate with clinical pheno-
type (5).
Candidate gene studies in IBM have focused mainly
on theMHC, and there are few validated associations outside
of this region. Genes associated with neurodegenerative dis-
eases such as Alzheimer’s Disease have been examined in
IBM, for example, the genes forb/A4-amyloid precursor pro-
tein and apolipoprotein E, although these studies frequently
have shown negative or conflicting results (6–8). Other candi-
date gene approaches have focused on autoantibody targets
(1) and genes previously implicated in hereditary inclusion
body myopathies (9,10). However, those studies also have
failed to find significant common associations.
We recently reported a genetic association study in
polymyositis (PM) and dermatomyositis (DM) using the
Immunochip array, a custom-designed, high-density geno-
typing chip that covers genes known to be associated with a
variety of autoimmune diseases (11). Samples from patients
with IBM were genotyped concurrently and were analyzed
separately in this analysis using a previously described
method of case–control matching to control for population
differences. Using the Immunochip, we have conducted the
largest genetic study to date in IBM to investigate potential
associations with immune-related genes, and we have used
imputation to refine associationswithin theMHC.
PATIENTS AND METHODS
Study populations. A total of 252 patients with IBM
from 11 countries were recruited through the Myositis Genetics
Consortium (MYOGEN). A list of MYOGEN study investigators
in addition to the authors of this article is provided in Appendix A.
Written informed consent was obtained from all patients with
approval from research ethics boards at each participating center.
Patients with IBMwere included if they fulfilled the following crite-
ria:Griggs (“definite” or “possible”) (12),Medical ResearchCoun-
cil (“pathologically defined,” “clinically defined,” or “possible”)
(13), or European Neuromuscular Centre (“clinico-pathologically
defined,” “clinically defined,” or “probable”) (14). Age at onset for
UK patients with IBM was the age at onset of first symptoms as
recorded in the clinical record.
Shared control samples from Sweden (the Epidemiologi-
cal Investigation of Rheumatoid Arthritis study), Spain, and The
Netherlands were provided by the Rheumatoid Arthritis Consor-
tium International (15), with control samples from the UK pro-
vided by the Wellcome Trust Case Control Consortium (16).
Control samples from Italy, Norway, Belgium, and France were
provided by the International Multiple Sclerosis Genetics Con-
sortium (17). Polish and Hungarian control samples were pro-
vided by the Celiac Consortium (18), and German control
samples were provided by the KORAgen consortium (19).
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Genotyping and quality control. Genotyping was per-
formed in accordance with Illumina’s protocols in theUK (Centre
for Genetics and Genomics Arthritis Research UK, University of
Manchester,Manchester, UK) and theUS (Feinstein Institute for
Medical Research, Manhasset, NY). Standard quality control was
performed as described previously (11). Four controls for each
case werematched for ethnicity using principal components analy-
sis coordinates using amethod described previously (20).
Statistical analysis. Statistical analyses were performed
in Plink version 1.7 (http://zzz.bwh.harvard.edu/plink/index.shtml)
using a logistic regression applying an additive model. Sex and
population differences were controlled for by including sex and
the top 10 principal components as covariates. Significance was
defined as P, 5 3 1028. We also reported variants reaching a
second tier of significance of P, 2.25 3 1025, calculated using
the genetic Type I Error Calculator (21). Odds ratios (ORs) are
provided with 95% confidence intervals (95% CIs).
To investigate associations with HLA and age at onset,
linear regressions were used, with P values less than 0.05 con-
sidered significant. Analyses were carried out using Stata sta-
tistical software version 13.1 (StataCorp).
Table 1. Numbers of samples from patients with inclusion body
myositis and ethnically matched controls included in the analysis
after quality control, by country of origin*
Patients Controls
Australia 44 –
Belgium 6 23
Czech Republic 2 –
France 19 35
Germany – 29
Hungary 2 7
Italy 2 44
The Netherlands 9 69
Norway 1 30
Poland – 8
Sweden 31 97
Spain 8 28
UK 128 485
US – 153
Total 252 1,008
* Control samples were shared from Immunochip consortia. Four
controls for each patient were matched based on nearest neighbor
by principal components analysis coordinates.
Figure 1. Manhattan plots of the inclusion body myositis (IBM) analysis. Red line represents genome-wide level of significance (P, 5 3 1028);
blue line represents suggestive significance (P, 2.25 3 1025). Shown is the analysis of 252 patients with IBM and 1,008 matched controls. A,
Manhattan plot of the total Immunochip analysis. B, Manhattan plot of the IBM analysis with the major histocompatibility complex (MHC)
region (chromosome 6 25–35) removed for visualization purposes. Color figure can be viewed in the online issue, which is available at http://
onlinelibrary.wiley.com/journal/doi/10.1002/art.40045/abstract.
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Functional annotation. Evidence for functional effects
and expression quantitative trait loci (eQTLs) were investigated for
the lead single-nucleotide polymorphisms (SNPs) in each region,
and SNPs in high linkage disequilibrium (LD) (r2$ 0.8) were
obtained fromPhase 3 1000Genomes data using LDlink (22).
MHC imputation and association analysis. Classic
HLA alleles and corresponding amino acid sequences were
imputed from Immunochip SNP data using the SNP2HLA pro-
gram as described previously (11). Significance was defined as
P, 6.8 3 1026 based on a Bonferroni correction of the 7,323
markers imputed by SNP2HLA (23). For consistency, the most
associated variant was used in the stepwise conditional analysis.
Molecular graphics were generated and analyses were performed
with the University of California, San Francisco (UCSF) Chimera
package version 1.10.2 (Resource for Biocomputing, Visualiza-
tion, and Informatics at UCSF).
Anti-cN1A detection. Enzyme-linked immunosorbent
assay detection of anti-cN1A antibodies was performed using the
optimized protocol as described previously (24). Briefly, biotinylated
peptides were incubated on Streptawell High Bind microplates
(Roche) for 1 hour at 378C to immobilize the peptides. Unbound
peptides were removed by washing the microplates 3 times. Diluted
patient serumwas then added to themicroplate followed by incuba-
tion at 378C for 1 hour. Unbound antigen was removed by further
washing the microplate 5 times. Diluted rabbit anti-human Ig was
then added, and the plate was incubated for 1 hour at 378C followed
by a further 5 washes. Finally, the bound antibodies were visualized
by adding substrate solution, and the reaction was stopped after 5
minutes by adding a stop solution. Signals were quantified by deter-
mining optical densities at 450 nm (OD450 nm). The OD450 nm value
corresponding to the highest Youden Index [calculated as:
([sensitivity/100]1 [specificity/100]2 1)] (25) at which$98% speci-
ficity was achieved was chosen for each peptide. Sera were assessed
as reactive if they were above the established cutoff value for at least
one of the peptide antigens (24).
RESULTS
Genotyping quality control. After stringent SNP
and sample quality control, we analyzed 104,636 genetic
variants in 252 patients with IBM and 1,008 ethnically
matched controls (Table 1). Including the top 10 principal
components as covariates and calculating the genomic
inflation on a set of null SNPs gave a lgc of 1.04, indicating
that patients and controls were well matched for ethnicity
(see Supplementary Figure 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40045/abstract).
HLA is the most strongly associated region in
IBM. SNPs within the MHC region were the only variants
reaching genome-wide significance of P, 5 3 1028 (Fig-
ure 1A). The strongest association was with rs3129950
(P5 3.583 10233), a SNP intronic of LOC101929163 and
3of BTNL2 (Table 2). As the Immunochip contains high-
density SNP coverage across the MHC, this region was
subsequently analyzed separately using HLA imputation
in an attempt to refine this association to a functional
gene. Initially, genes independent of the MHC were inves-
tigated that reached a suggestive level of significance.
Suggestive significance of 3 non-HLA associations.
Three non-HLA regions reached our second tier of signifi-
cance (defined as P, 2.25 3 1025) calculated using the
genetic Type I Error Calculator (21). Figure 1B shows the
Manhattan plot with the MHC region removed for visuali-
zation purposes. The most convincing associations were in
the chromosome 3 p21.31 region, where 49 SNPs reached
the suggestive level of significance (Figure 2). The strongest
association was upstream of CCR2 (rs112088397, P5 1.93
3 1026, OR 0.42 [95% CI 0.29–0.60]); however, this haplo-
type contains many genes including CCR3, CCR2, CCR5,
andCCRL2.
Potentially functional variants were investigated for
all non-HLA SNPs reaching suggestive significance and
those tagged by the lead SNP (r2$ 0.8) (see Supplementary
Table 2. Analysis of the 252 patients with inclusion body myositis compared to 1,008 ethnically matched controls*
Gene
region Chr. Position SNP
Minor
allele
MAF in
patients
MAF in
controls P
OR
(95% CI)
Localization of
LD to nearest genes
(r2$ 0.9)
MHC 6 32358201 rs3129950 C 0.34 0.11 3.58 3 10233† 5.69
(4.28–7.55)
MHC
CCR3/CCR2 3 46389462 rs112088397 T 0.08 0.16 1.93 3 1026‡ 0.42
(0.29–0.60)
Downstream of CCR3
to intron 2 of LTF;
incorporating CCR2,
CCR5, and CCRL2
FLJ14816/GLI2 2 121338584 rs1880542 T 0.56 0.45 5.66 3 1026‡ 1.60
(1.31–1.96)
Intergenic of
FLJ14816 and GLI2
LOC100128517/
LOC728961
6 14560180 rs9396510 T 0.11 0.05 7.52 3 1026‡ 2.23
(1.57–3.17)
Intergenic of
LOC100128517
and LOC728961
* Coordinates are based on the human assembly GRCh37. Chr.5 chromosome; SNP5 single-nucleotide polymorphism; MAF5minor allele fre-
quency; OR5 odds ratio; 95% CI5 95% confidence interval; LD5 linkage disequilibrium.
† Reported at genome-wide significance (P, 5 3 1028).
‡ Reported at second tier of significance (P, 2.25 3 1025).
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Tables 1–3, http://onlinelibrary.wiley.com/doi/10.1002/art.
40045/abstract). Multiple SNPs within the chromosome 3
p21.31 region had evidence for eQTLs for the expression of
CCR5 in monocytes (26). There was 1 missense SNP in the
chromosome 3 p21.31 region (rs6441977) that was predicted
to be “benign” by PolyPhen-2 (27); however, a frameshift
mutation (rs333) is a known variant that results in a 32-bp
deletion and a nonfunctional receptor. Conditional analysis
on this locus did not identify additional independent
variants.
HLA imputation reveals association with HLA–
DRB1. To refine associationswithin theMHCregion,HLA
alleles were imputed fromSNP genotyping information using
SNP2HLA (23). Variants reaching statistical significance
(P, 6.8 3 1026) after each round of conditioning are
included in Supplementary Tables 4–6, http://onlinelibrary.
wiley.com/doi/10.1002/art.40045/abstract. The strongest asso-
ciations were with alleles that are part of the 8.1 ancestral
haplotype, with HLA–DRB1*03:01 reaching P5 5.77 3
10234 (OR 7.97 [95% CI 5.88–10.95]). Due to strong LD
within the MHC, other alleles within this haplotype such as
HLA–DQB1*02:02 andHLA–B*08:01 also had strong asso-
ciations in this analysis; however, these lost significance after
conditioning on the effect ofHLA–DRB1*03:01.Conducting
stepwise conditional analysis on significant HLA–DRB1
alleles, an independent effect was seen with HLA–DRB1*
01:01 (P5 1.56 3 10216, OR 4.64 [95% CI 3.33–6.49]). A
further independent effect was seen with HLA–DRB1*
13:01 (P5 3.283 1028,OR3.19 [95%CI 2.14–4.72]).
As risk may lie within multiple HLA alleles, we
imputed amino acids to investigate whether shared positions
within risk alleles might explain the risk at this locus (see
Supplementary Tables 7 and 8, http://onlinelibrary.wiley.
com/doi/10.1002/art.40045/abstract). Amino acid position 26
of HLA–DRB1 was associated more significantly than a sin-
gle classic HLA allele (P5 5.223 10243), with risk attribut-
able to a tyrosine at this position (OR 3.83 [95% CI 2.80–
5.29]) (Table 3). This contrasts with PM and DM, where
HLA–DRB1 amino acid position 77 was the most strongly
associated position (Table 3). Conditioning on the effects of
position 26 in IBM revealed an independent effect of posi-
tion 11 of HLA–DRB1 (P5 3.803 10213). At this position,
serine is the most common amino acid in the population
and was therefore used as the reference. As many other
amino acids are protective at this position, we can infer that
serine confers the greatest risk. No further amino acid posi-
tions were statistically significant after conditioning on posi-
tions 26 and 11 of HLA–DRB1.
Figure 2. Regional association plot of the chromosome 3 (Chr3) p21.31 region in inclusion body myositis. The plot shows strength of association
(2log10[P]) against chromosomal position. The most strongly associated single-nucleotide polymorphism (SNP) is colored purple, with other
SNPs colored by the degree of linkage disequilibrium (r2). Local recombination rates estimated from the HapMap population of Utah residents
with ancestry from northern and western Europe are plotted against the secondary y-axis, showing recombination hotspots across the region.
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No distinct HLA association with anti-cN1A posi-
tivity. Anti-cN1A antibodies were detected in 36 of the
104 patients serologically tested (35%). After quality con-
trol, HLA imputation was conducted on 35 anti-cN1A–
positive patients and 140 healthy controls, and themost sig-
nificant 4-digit classic HLA association was found with
HLA–DRB1*03:01 (P5 5.62 3 1028, OR 11.52 [95% CI
4.95–29.29]) (see Supplementary Table 9, http://onlinelibrary.
wiley.com/doi/10.1002/art.40045/abstract). After stepwise
conditional analysis, we did not find any additional indepen-
dent effects. We then compared the 35 anti-cN1A–positive
patients with 68 anti-cN1A–negative patients, and we found
no significant differences in HLA associations between these
groups (data not shown).
No effect of HLA–DRB1 allele interactions on
age at onset. Previous studies have suggested that HLA–
DRB1 alleles may have disease-modifying effects in IBM,
with the HLA–DRB1*03/*01 genotype conferring an ear-
lier age at onset and more severe muscle weakness (5,28).
HLA and age at onset data were available for 124 UK
patients with IBM. Linear regression was used to analyze
the relationship of HLA–DRB1 alleles with age at onset.
No significant associations were found with risk alleles
HLA–DRB1*01:01, DRB1*03:01, or DRB1*13:01 when
these were analyzed separately or in combination (see
Supplementary Table 10, http://onlinelibrary.wiley.com/
doi/10.1002/art.40045/abstract).
DISCUSSION
This is the largest genetic association study to date
in Caucasian patients with IBM. The results confirm that
HLA is the most strongly associated region, identify multi-
ple HLA–DRB1 alleles conferring risk, and suggest amino
acid positions that may explain the risk in this locus. A
novel suggestive association within the chromosome 3
p21.31 locus indicates genetic overlap with other autoim-
mune diseases and identifies a potentially functional vari-
ant that may contribute to the pathogenesis of IBM.
HLA imputation confirmed that the strongest risk
within this region lies with HLA–DRB1*03:01. Stepwise
conditional analyses revealed additional independent asso-
ciations with HLA–DRB1*01:01 and HLA–DRB1*13:01,
suggesting that the HLA–DRB1 gene is important in sus-
ceptibility to IBM. In contrast to previous studies, there
were no significant associations of age at onset with HLA–
DRB1 alleles. Other reported disease-modifying effects of
HLA alleles in IBM, such as with disease severity and
lower quadriceps muscle strength, were not investigated
due to a lack of consistent clinical data across this multi-
national, multicenter study. Previous studies have also
investigated additional risk factors present on the MHC,
such as polymorphisms in the gene for Notch-4 (29) or car-
riage of secondary HLA–DRB loci such as HLA–DRB3
(30). Although not explicitly investigated in the present
study, these associations are in strong linkage with the 8.1
ancestral haplotype, and we do not expect our data to dif-
ferentiate between these risk factors. Conditioning on the
presence of HLA–DRB1, no additional genetic variants
within the MHC region were associated with IBM. The
frequency of genotypes among patients with IBM (see Sup-
plementary Table 10, http://onlinelibrary.wiley.com/doi/10.
1002/art.40045/abstract) suggests that patients homozygous
for HLA–DRB1*03:01 and DRB1*01:01 are at lower risk
of disease. The contribution of nonadditive effects across
HLA alleles has been reported in several autoimmune dis-
eases and may explain higher risk for heterozygote individu-
als (31). The small numbers in this cohort mean that the
study is underpowered to statistically test this in IBM.
As multiple HLA–DRB1 alleles were associated
with IBM, we investigated whether there were shared
amino acid positions within HLA–DRB1 risk alleles
that might explain the risk at this locus. Position 26 of
HLA–DRB1 was more strongly associated than a classic
HLA allele alone (P5 5.22 3 10243 versus P5 5.77 3
10234). An additional independent effect was found
Table 3. Independent associations of HLA–DRB1 amino acids in
clinical subgroups of idiopathic inflammatory myopathy*
Association, marker P OR (95% CI)
Most associated in
inclusion body
myositis
Position 26 Omnibus 5.22 3 10243
Phenylalanine Reference† 1
Tyrosine 1.19 3 10216 3.83 (2.8–5.29)
Leucine 0.32 0.63 (0.24–1.48)
Position 11 Omnibus 3.80 3 10213
Serine Reference† 1
Proline 9.06 3 1025 0.42 (0.27–0.64)
Valine 2.25 3 1026 0.33 (0.2–0.51)
Glycine 4.46 3 1026 0.26 (0.14–0.45)
Leucine 0.03 2.75 (1.15–7.5)
Aspartic acid 1.41 3 1023 0.13 (0.03–0.39)
Most associated in
polymyositis‡
Position 77 Omnibus 1.65 3 10280
Threonine Reference† 1
Asparagine 1.65 3 10280 2.93 (2.53–3.17)
Most associated in
dermatomyositis‡
Position 77 Omnibus 1.37 3 10236
Threonine Reference† 1
Asparagine 1.37 3 10236 2.14 (1.90–2.41)
* P values and odds ratios (ORs) with 95% confidence intervals
(95% CIs) were calculated in a logistic regression.
† Reference amino acid is taken as the most frequent in the
population.
‡ For comparative purposes, HLA–DRB1 amino acid association sta-
tistics for polymyositis and dermatomyositis are shown (from ref. 11).
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with position 11 of HLA–DRB1. Positions 11 and 26
have been associated previously with seropositive autoim-
mune disease, such as systemic lupus erythematosus (32),
which suggests that these positions may determine prop-
erties of the HLA–DRB1 peptide-binding groove, al-
lowing it to preferentially bind autoantigenic peptides
(Figure 3). Certain amino acids, such as a tyrosine at
position 26 and serine at position 11, were associated
with risk in this analysis; however, a lack of statistical
power means that we were unable to completely charac-
terize the effects of certain amino acids in this molecule.
It is interesting to note that while IBM shares HLA–
DRB1*03:01 as a significant risk factor with other inflam-
matory myopathies, such as PM and DM, the amino acid
associations differ between these subtypes. In PM and
DM, amino acid position 74 of HLA–DRB1 explains
almost all of the risk within this gene (11). These differ-
ences in amino acid associations may be explained by the
additional independent effects of HLA–DRB1*01:01
and HLA–DRB1*13:01 in IBM that are not associated
with PM or DM. Understanding the peptide-binding
specificities of these risk alleles may inform future
research along with the potential identification of unique
autoantigens presented to the immune system in IBM.
We investigated potential associations between
specific HLA alleles and the newly described anti-cN1A
antibody. The significant association observed with
HLA–DRB1*03:01 and the anti-cN1A antibody may be
due to an increased association with HLA–DRB1*03:01
as a whole in IBM. No significant differences in HLA
associations were observed between anti-cN1A–positive
and anti-cN1A–negative patients. A recent study in an
Australian cohort of patients also failed to show any
association with anti-cN1A antibodies and MHC class II
alleles other than HLA–DR3 (33). Furthermore, we do
not have complete data on co-occurrence of anti-cN1A
and other antibodies, such as anti-Ro, which also has a
strong HLA–DR3 association (34). It may be that a sig-
nificantly larger sample size is needed to detect novel
HLA associations in patients with anti-cN1A antibodies.
The Immunochip is a custom-designed chip that
contains a dense set of SNPs covering 186 loci based on
evidence of association with 12 different autoimmune
and inflammatory diseases (18). Therefore, the current
study tests a specific hypothesis that IBM shares genetic
overlap with other autoimmune diseases. The current
study has not comprehensively tested other loci that
have been purported to be associated with IBM, such as
those predisposing to hereditary inclusion body myopa-
thies or loci associated with other degenerative diseases.
The observation that the MHC region is strongly associ-
ated, and evidence of association with other genes on
Figure 3. Locations of positions 26 and 11 of HLA–DRB1 within DR b-chain 1. Positions 26 and 11 are independently associated with inclusion
body myositis. Arrows indicate the locations of the risk-conferring amino acids Tyr26 and Ser11 within the b-sheet floor of DR b-chain 1. Color
figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/journal/doi/10.1002/art.40045/abstract.
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this array, suggests an immune-mediated component to
IBM. It is not clear whether this represents a primary or
secondary involvement.
No non-HLA loci investigated reached genome-
wide significance, although this is to be expected in a study
of this size. While comparatively large for IBM, this study
is underpowered to detect associations of small effect sizes
that are expected in genetic studies of conditions with com-
plex etiologies. Three loci did reach a suggestive level of
significance (P, 2.253 1025). Of particular interest is the
chromosome 3 p21.31 region, which is known to be associ-
ated with multiple autoimmune diseases such as celiac dis-
ease, type 1 diabetes mellitus, and Behc¸et’s disease and is
suggestively associated in juvenile idiopathic arthritis (JIA)
(35–38). The strongest association in this region was with
rs112088397, which tags a large haplotype block where
many additional SNPs reached a suggestive level of signifi-
cance and is the same risk haplotype as that reported in
JIA (r25 0.87) (35,39). The variant rs112088397 in our
study is found at a higher frequency in controls (minor
allele frequency [MAF] of 0.08 for patients versus MAF of
0.16 for controls) and is therefore protective against IBM
(OR 0.42 [95% CI 0.29–0.60]). Proxies for rs112088397 fall
within multiple candidate genes including CCR1, CCR3,
CCR2, CCR5, and CCRL2, and therefore it is difficult to
identify the causal variant in this region. Interestingly, this
haplotype contains a frameshift mutation (rs333) that
results in a 32-bp deletion variant (CCR5D32) and a non-
functional receptor. The most strongly associated non-
HLA SNP in IBM is in high LD with this frameshift muta-
tion (r25 0.86); furthermore, a number of SNPs in this
region are eQTLs for the expression of CCR5 in mono-
cytes (26).
CCR5 binds a number of proinflammatory chemo-
kines that are up-regulated in IIMs and IBM, such as CCL3
(macrophage inflammatory protein 1a [MIP-1a]), CCL4
(MIP-1b), and CCL5 (RANTES). CCR5 has been shown to
be predominantly expressed on monocytes, macrophages,
and T cells, up-regulated in IBMmuscle tissue, and localized
on inflammatory cells invading nonnecrotic muscle fibers
(40,41). Interestingly, in rheumatoid arthritis (RA) the den-
sity of CCR5molecules on the T cell surface determines effi-
ciency of its function as a chemokine receptor and intensity of
T cell migration toward RA synoviocytes (42). We hypothe-
size that CCR5 is important in the pathogenesis of IBM, con-
sistent with studies showing an up-regulation of CCR5 in
muscle tissue of patients. Individuals with the protective
rs333 frameshift mutation described above will carry a non-
functional variant and/or decreased expression of CCR5,
resulting in reducedmigration of T cells intomuscle fiber.
It is interesting that the suggestive association with
the chromosome 3 p21.31 region in this study was found
with only 252 individuals. This may be explained by the
stronger effect size in IBM compared to JIA (0.42 versus
0.78, respectively) (35), and although IBM is a rare disease,
it may mean that replication of this association is possible
with ongoing sample collection. Due to the rarity of IBM,
it is difficult to ascertain the sample sizes needed for
genome-wide association studies; therefore, next-generation
sequencing could be an approach to detect rare, potentially
functional variants of large effect size. Sequencing studies
are currently underway taking either a candidate gene
approach (10) or a hypothesis-free approach sequencing
exomes of a large number of patients with IBM (9). The
present study has not comprehensively tested other loci that
have been purported to be associated with IBM, such as
those predisposing to hereditary inclusion body myopathies
or loci associated with other degenerative diseases. In a dis-
ease in which the etiology is unknown, sequencing could be
successful in identifying novel variants and/or pathways
involved in disease pathogenesis.
In summary, we have conducted the largest
genetic association study to date in Caucasian patients
with IBM, confirming the involvement of an immune-
mediated genetic component of this understudied dis-
ease. Studies in the genetics of IBM are hampered by
small sample sizes due to the rarity of this disease.
Ongoing sample collection, as well as further interna-
tional collaborative studies, will allow us to further char-
acterize genetic influences on susceptibility to IBM.
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(John Radcliffe Hospital, Oxford, UK), Patrick Kiely (St. George’s
Hospital, London, UK), and Herman Mann (Institute of Rheumatol-
ogy, Prague, Czech Republic).
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Clinical Images: Widening of joint spaces in acromegaly
The patient, a previously healthy 51-year-old man, presented with migratory joint pain on the lower extremities lasting for several
months. His shoe size had increased by 0.6 inches. Physical examination revealed enlargement of the fingers and toes. Radiography
of the hands (A) and feet (B) showed widening of the joint spaces on some of the metacarpophalangeal and metatarsophalangeal
joints (arrows), along with tufting of the terminal phalanges. The serum insulin-like growth factor 1 concentration was 1,380 mg/ml
(normal 87–243). Magnetic resonance imaging of the pituitary gland (T1-weighted image with contrast) showed a poorly enhanced
tumor of 9 mm in the sella turcica. Acromegaly was diagnosed and the brain tumor was resected. Acromegaly is characterized by
acral enlargement, with initial presentation sometimes being hypertrophic arthropathy. Radiographs showing widening of joint
space due to cartilage enlargement can be a clue to the diagnosis.
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